Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 CAR-T Cell Therapy in Autoantibody-Mediated Autoimmune Diseases
NCT07596680Phase 1Not yet recruiting
- Sponsor
- Bioheng Therapeutics
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 2 more, sponsored by Bioheng Therapeutics. Primary endpoints: Systemic Lupus Erythematosus Primary Endpoint at 2 years, ANCA-Associated Vasculitis Primary Endpoint at 2 years and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RD06-05
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07596680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596680.